# COST AND UTILIZATION TRENDS OF PERCUTANEOUS KIDNEY BIOPSY IN KIDNEY TRANSPLANT PATIENTS: A 4-YEAR CLAIMS DATA ANALYSIS

# Authors:

# Adrian Vilalta, PhD

Outcomes Metrics LLC, San Diego, CA USA

ORCID: https://orcid.org/0000-0003-0379-8276 Email: Adrian.Vilalta@outcomesmetrics.com

## **Conflicts of Interest:**

The author received financial support from CareDx, Inc. for the research, writing and publication of this article.

# ABSTRACT

**Objective:** This study evaluated patterns of utilization and costs of percutaneous kidney biopsies in kidney transplant patients.

**Methods:** The IBM *Treatment Pathways* tool was used to interrogate cohorts selected from the IBM *MarketScan* dataset. Analyses were done for both adult and pediatric patients. Differences in biopsy paid amounts and utilization patterns were assessed for commercial payers, Medicare, and Medicaid. Claims data were collected for the years 2016 to 2019.

**Results:** A total of 15,337 records for percutaneous kidney biopsy events performed between 2016 and 2019 were identified in the database. Out of these, 840 corresponded to pediatric patients.

**Discussion:** Analysis showed that the paid amount for the procedure increased by 10% from 2016 to 2019 for commercial payers for adult patients, with US \$4,137 being the median paid amount in 2019. Median paid amounts by both Medicare and Medicaid remained essentially flat for the same time at US \$2,063 for Medicare and US \$865 for Medicaid in 2019. Median cost of the procedure in pediatric patients increased 17% between 2016 and 2019 for commercial payers being US \$6,068 in 2019. Medicaid payments for the pediatric patient population showed little change between 2016 and 2019, being US \$1,666 in 2019.

Keywords: kidney biopsy, kidney transplant, cost

## INTRODUCTION

Kidney transplantation is a lifesaving, last resort measure for people with end-stage kidney disease. It is estimated that close to 250 thousand people are alive today with a functioning kidney graft.<sup>1</sup> However, kidney transplantation and graft health surveillance represent a significant financial burden. The estimated billed charges for a kidney transplant exceed US \$440k and the average patient graft failure is predicted to incur additional lifetime medical costs of US \$78,079.<sup>2,3</sup> Percutaneous kidney biopsies are used routinely to both monitor the allograft's health as well as to help diagnose any transplant complications such as rejection. Percutaneous kidney biopsy is commonly performed as an outpatient procedure under local anesthesia. Ultrasound is often used to guide the biopsy needle, determine kidney size, and detect the presence of cysts. Computed tomography imaging (CT) is used as an alternative for patients with small kidneys or high BMI.<sup>4</sup> Although kidney biopsies are performed routinely, they present a risk of post-procedure complications ranging from pain at the biopsy site, to post-procedure hemorrhage, perinephric hematomas, and death.<sup>5-7</sup>

Despite being used routinely, there is a lack of current, real-world data on the financial cost of kidney biopsies, especially as it pertains to the kidney transplant population. Existing financial cost estimates are based on anecdotal, limited, outdated data sets or models.<sup>8-10</sup> Importantly, actual payment data are required as bill charges overestimate actual payment for services.

The present study aimed to generate accurate, current, and complete data on the financial cost in US dollars of an outpatient kidney biopsy event by payer type for adults and pediatric kidney transplant patients.

# METHODS

Data presented here were obtained through a retrospective, observational claims-based analysis using a de-identified database to describe the patterns of utilization and episode costs of percutaneous kidney biopsies in kidney transplant patients.

# Patient Selection

Patients with evidence of a percutaneous kidney biopsy outpatient event and enrollment in either a commercial, Medicare, or Medicaid insurance plan were identified through the IBM<sup>®</sup> *MarketScan*<sup>®</sup> *Treatment Pathways*<sup>®</sup> database and analytical interface.<sup>11</sup> *MarketScan*<sup>®</sup> collects all the coordination of benefits (COB) data thus generating total amount paid information, i.e., insurance, co-insurance, and patient pay. The event comprised all procedures performed the day of the kidney biopsy as defined by CPT 50200 in the claim. The cohort was further refined by selecting individuals with evidence of kidney transplantation. We also analyzed utilization and kidney biopsy costs in the pediatric population as defined by the American Academy of Pediatrics (21-years or younger).<sup>12</sup> We obtained data for calendar years 2016 through 2019. During that period, the IBM<sup>®</sup> *MarketScan*<sup>®</sup> database contained the de-identified annual pooled healthcare data for over 48 million individuals with at least one year of data close to 200 million individuals insured commercially, or as part of the national distributed Supplemental Medicare and Medicaid programs throughout the entire United States. No IRB review was required given the nature of this study and the de-identified data source utilized.

# Study Measures

Evidence of transdermal kidney biopsy was established using Current Procedural Terminology (CPT) codes. The CPT code set is maintained by the American Medical Association.<sup>13</sup> Diagnosis of kidney transplantation was established using International Classification of Diseases (ICD-9 and ICD-10) codes. ICD codes are created by the World Health Organization and contain codes for diseases, signs and symptoms, abnormal findings, complaints, social circumstances, and external causes of injury or diseases.<sup>14</sup> Details on codes used in the present study can be found in **SUPPLEMENT 1**.

### Limitations

As with other claims-based studies, the findings may be impacted by the sensitivity of the claims data. Cohorts defined by this analysis do not consist of the complete universe of

patients receiving the procedure. Only outpatient claims were included in the present analysis therefore costs of episodes systematically omit any inpatient services incurred through treatment of complications. Claims data may underestimate health care utilization among low-income individuals including Medicaid-insured and the non-insured population.

# **STUDY RESULTS**

Number of records identified for adult and pediatric patients from 2016 to 2019 are presented in **Figure 1.** Paid amounts per episode of care for adults are summarized in **Table 1.** Paid amounts for episode of care for pediatric patients ( $\leq$  21 years) are presented in **Table 2.** We performed a proximate event analysis using the code for percutaneous kidney biopsy (CPT 50200) as the index code. This analysis identified procedures associated with CPT 50200 and their frequency the day of the kidney biopsy. The proximate event analysis was done to better understand the composition of procedures contributing to the total paid amount of the kidney biopsy episode of care. The list of the top 100 codes co-appearing in the kidney biopsy claims is provided in **SUPPLEMENT 2**.

According to our analysis, the median paid amount for a percutaneous kidney biopsy event for an adult patient by commercial payers has increased steadily from 2016 (\$3,778) to 2019 (\$4,137) in kidney transplant patients. The increase is even higher (17%) for biopsies performed in the pediatric kidney transplant population, ranging from a median of \$5,169 in 2016 to \$6,068 in 2019. Remarkably, the paid amount for the procedure is close to 40 % higher in pediatric patients compared to the overall cohort, reflecting the complexities associated with performing the procedure in younger patients. While the paid amounts by commercial payers have increased, the paid amounts by both Medicare and Medicaid have remained relatively unchanged from 2016 to 2019. Our analysis indicated a median Medicare payment of \$2,063 for the kidney biopsy event in 2019. According to Medicare, the national average total cost of the procedure in 2021 is \$1,535, with \$128 covering doctor's fees, \$1,407 facility fees, and the patient being responsible for \$306.<sup>15</sup> The higher paid amount revealed by our analysis reflects payment for additional services required the day of the biopsy event.

Our analysis also revealed a steady increase in the number of procedures performed year over year. The increase in the number of procedures from 2016 to 2019 ranges from about 16% if only commercially paid procedures are considered to close to 35% when procedures paid by Medicare and Medicaid are included. In the same period, the total number of kidney transplants reported in 2016 was 14,745 increasing to 18,018 in 2019, representing a 22 % increase in kidney transplantations.<sup>16</sup> Although our data do not include every single transplant patient during the time window of the study, the increase in the identified kidney biopsy claims tracks with the increase in the number of kidney transplantations. However, estimates of the number of biopsies received by transplant patients and whether they have changed over time would require further analysis.

# CONCLUSIONS

Percutaneous kidney biopsy is a routine, recurrent procedure used to monitor the health of kidney allografts as well as to help diagnose potential complications. Spite its wide use, there is a paucity of recent, real-world data on paid amounts for the procedure, as well as the total cost of the episode of care. These data are essential to enable the development of clinico-economic models of clinical interventions that potential impact the number of subcutaneous kidney biopsies performed.

The present analysis bridged the data gap by providing paid amounts for the complete episode of care by payer type. The analysis also revealed significant differences in the cost of the procedure for pediatric kidney transplant patients compared to the kidney transplant population at large. In addition, the analysis showed trends in both the paid amount as well as the number of procedures performed. The cost and patterns of utilization established here provide a solid foundation for follow up analyses of the economic value of alternative allograft surveillance strategies.

# REFERENCES

1. Scientific Registry of Transplant Recipients. (Accessed September 7, 2020, at <u>https://www.srtr.org/</u>.)

2. Bentley TS, Ortner NJ. Milliman Research Report U.S. organ and tissue transplants: Cost estimates, discussion, and emerging issues. 2020.

3. Sussell J, Silverstein AR, Goutam P, et al. The economic burden of kidney graft failure in the United States. Am J Transplant 2020;20:1323-33.

4. Korbet SM. Percutaneous renal biopsy. Semin Nephrol 2002;22:254-67.

5. Poggio ED, McClelland RL, Blank KN, et al. Systematic Review and Meta-Analysis of Native Kidney Biopsy Complications. Clin J Am Soc Nephrol 2020;15:1595-602.

6. Al Turk AA, Estiverne C, Agrawal PR, Michaud JM. Trends and outcomes of the use of percutaneous native kidney biopsy in the United States: 5-year data analysis of the Nationwide Inpatient Sample. Clin Kidney J 2018;11:330-6.

7. Aaltonen S, Finne P, Honkanen E. Outpatient Kidney Biopsy: A Single Center Experience and Review of Literature. Nephron 2020;144:14-20.

8. Dutta R, Okhunov Z, Vernez SL, et al. Cost Comparisons Between Different Techniques of Percutaneous Renal Biopsy for Small Renal Masses. J Endourol 2016;30 Suppl 1:S28-33.

9. Maripuri S, Penson DF, Ikizler TA, Cavanaugh KL. Outpatient versus inpatient observation after percutaneous native kidney biopsy: a cost minimization study. Am J Nephrol 2011;34:64-70.

10. McMahon GM, McGovern ME, Bijol V, et al. Development of an outpatient native kidney biopsy service in low-risk patients: a multidisciplinary approach. Am J Nephrol 2012;35:321-6.

11. IBM MarketScan Research Databases for Life Sciences Researchers. 2021. (Accessed 6/15/2021, at <a href="https://www.ibm.com/downloads/cas/OWZWJ0QO">https://www.ibm.com/downloads/cas/OWZWJ0QO</a>.)

12. Hardin AP, Hackell JM, Committee On P, Ambulatory M. Age Limit of Pediatrics. Pediatrics 2017;140.

13. The American Medical Association (AMA). CPT<sup>®</sup> (Current Procedural Terminology). (Accessed 6/2/2021, at <u>https://www.ama-assn.org/amaone/cpt-current-procedural-terminology</u>.)


14. The World Health Organization (WHO). International Statistical Classification of Diseases and Related Health Problems (ICD). (Accessed 6/2/2021, at

https://www.who.int/standards/classifications/classification-of-diseases.)

15. Renal biopsy; percutaneous, by trocar or needle. Code: 50200. (Accessed 6/29/2021, at <a href="https://www.medicare.gov/procedure-price-lookup/cost/50200/">https://www.medicare.gov/procedure-price-lookup/cost/50200/</a>.)

16. Organ Procurement and Transplantation Network. "National Data on the Candidate Waiting List, Organ Donation and Matching, and Transplantation.". (Accessed 8/19/2020, at <a href="https://optn.transplant.hrsa.gov/data/">https://optn.transplant.hrsa.gov/data/</a>.)

**Figure 1. Percutaneous kidney biopsy records 2016 to 2019**. (A) number of claims identified that met the inclusion criteria (i.e., CPT 50200 and evidence of kidney transplant) broken down by payer type. Total number of claims identified for each year is shown above the trendline. (B) number of claims identified for patient population 21 years of age or younger, broken down by payer type.



# TABLE 1

	Percutaneous Kidr Paid Amounts per Episode Mean	
2016 Commercial Insurance	\$4,675	\$3,778
Medicare Insurance	\$3,956	\$1,939
Medicaid Insurance	\$1,645	\$1,245
2017		
Commercial Insurance	\$4,985	\$3,980
Medicare Insurance	\$5,405	\$1,951
Medicaid Insurance	\$1,308	\$706
2018		
Commercial Insurance	\$5,170	\$4,180
Medicare Insurance	\$6,436	\$2,809
Medicaid Insurance	\$1,504	\$878
2019		
Commercial Insurance	\$5,404	\$4,137
Medicare Insurance	\$6,289	\$2,063
Medicaid Insurance	\$1,413	\$865

# TABLE 2

	Percutaneous Kidney Biopsy - Paid Amounts per Episode of Care (US \$) Pediatric	
	Mean	Median
2016		
Commercial Insurance	\$6,302	\$5,169
Medicaid Insurance	\$2,598	\$2,225
2017		
Commercial Insurance	\$7,255	\$5,045
Medicaid Insurance	\$2,682	\$2,430
2018		
Commercial Insurance	\$7,634	\$5,716
Medicaid Insurance	\$2,467	\$2,011
2019		
Commercial Insurance	\$7,831	\$6,068
Medicaid Insurance	\$2,616	\$1,666

## SUPPLEMENT 1 - CODES USED TO IDENTIFY CLAIMS DATA

#### PERCUTANEUS KIDNEY BIOPSY

## СРТ

50200- Needle biopsy of kidney, accessed through the skin

## **KIDNEY TRANSPLANT**

# СРТ

50360 - Renal allotransplantation, implantation of graft; without recipient nephrectomy

50365 - Renal allotransplantation, implantation of graft; with recipient nephrectomy

50370 - Removal of transplanted renal allograft

50380 – Renal auto transplantation, reimplantation of kidney

## ICD-10-PCS

OTY00Z0 – Transplantation of right kidney, allogeneic, open approach

0TY00Z1 – Transplantation of right kidney, syngeneic, open approach

0TY00Z2 – Transplantation of right kidney, zooplastic, open approach

0TY10Z0 – Transplantation of left kidney, allogeneic, open approach

0TY10Z1 – Transplantation of left kidney, syngeneic, open approach

0TY00Z2 - Transplantation of left kidney, zooplastic, open approach

# SUPPLEMENT 2- MOST FREQUENT CODES CO-APPEARING IN OUTPATIENT KIDNEY BIOPSY CLAIMS

Code	Event Name	Frequency (%)
50200	Renal biopsy; percutaneous, by trocar or needle	100.0
88305	Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation	55.1
88313	Special stain including interpretation and report; Group II, all other (e.g., iron, trichrome), except stain for microorganisms, stains for enzyme constituents, or immunocytochemistry and immunohistochemistry	47.1
88346	Immunofluorescence, per specimen; initial single antibody stain procedure	36.0
88348	Electron microscopy, diagnostic	32.7
88350	Immunofluorescence, per specimen; each additional single antibody stain procedure (list separately in addition to code for primary procedure)	47.0
77012	Computed tomography guidance for needle placement (e.g., biopsy, aspiration, injection, localization device), radiological supervision and interpretation	33.8
85610	Prothrombin time;	23.9
76942	Ultrasonic guidance for needle placement (e.g., biopsy, aspiration, injection, localization device), imaging supervision and interpretation	31.5
99152	Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in	23.5
J3010	Injection, fentanyl citrate, 0.1 mg	18.9
J2250	Injection, midazolam hydrochloride, per 1 mg	18.7
36415	Collection of venous blood by venipuncture	13.3
88342	Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure	18.2
85730	Thromboplastin time, partial (PTT); plasma or whole blood	13.8
85027	Blood count; complete (CBC), automated (Hgb, HCT, RBC, WBC and platelet count)	12.5
85025	Blood count; complete (CBC), automated (Hgb, HCT, RBC, WBC and platelet count) and automated differential WBC count	12.4
99153	Moderate sedation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent trained observer to assist in	10.8

88341	Immunohistochemistry or immunocytochemistry, per specimen; each additional single antibody stain procedure (List separately in addition to code for primary procedure)	13.0
88329	Pathology consultation during surgery;	7.5
80048	Basic metabolic panel (Calcium, total) This panel must include the following: Calcium, total (82310) Carbon dioxide (bicarbonate) (82374) Chloride (82435) Creatinine (82565) Glucose (82947) Potassium (84132) Sodium (84295) Urea nitrogen (BUN) (84520)	7.7
88300	Level I - Surgical pathology, gross examination only	8.4
85014	Blood count; hematocrit (HCT)	5.1
85018	Blood count; hemoglobin (Hgb)	4.6
86900	Blood typing, serologic; ABO	4.0
86901	Blood typing, serologic; Rh (D)	4.0
86850	Antibody screen, RBC, each serum technique	3.9
81001	Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, with microscopy	3.4
80053	Comprehensive metabolic panel This panel must include the following: Albumin (82040) Bilirubin, total (82247) Calcium, total (82310) Carbon dioxide (bicarbonate) (82374) Chloride (82435) Creatinine (82565) Glucose (82947) Phosphatase, alkaline (84075	3.4
J7030	Infusion, normal saline solution, 1000 cc	2.8
J2001	Injection, lidocaine HCl for intravenous infusion, 10 mg	2.9
80197	Tacrolimus	3.0
85049	Blood count; platelet, automated	2.8
J2405	Injection, ondansetron hydrochloride, per 1 mg	2.7
83735	Magnesium	2.8
84156	Protein, total, except by refractometry; urine	2.7
G0378	Hospital observation service, per hour	2.8
82570	Creatinine; other source	2.6
87799	Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; quantification, each organism	2.7
82962	Glucose, blood by glucose monitoring device(s) cleared by the FDA specifically for home use	2.8
80069	Renal function panel This panel must include the following: Albumin (82040) Calcium, total (82310) Carbon dioxide (bicarbonate) (82374) Chloride (82435) Creatinine (82565) Glucose (82947) Phosphorus inorganic (phosphate) (84100) Potassium (84132) Sod	2.5
84100	Phosphorus inorganic (phosphate);	2.3
860	Anesthesia for extraperitoneal procedures in lower abdomen, including urinary tract; not otherwise specified	2.5
88333	Pathology consultation during surgery; cytologic examination (e.g., touch prep, squash prep), initial site	2.9
J7040	Infusion, normal saline solution, sterile (500 ml = 1 unit)	1.9

86832	Antibody to human leukocyte antigens (HLA), solid phase assays (e.g., microspheres or beads, ELISA, Flow cytometry); high-definition qualitative panel for identification of antibody specificities (e.g., individual antigen per bead methodology), HLA Class	1.9
82565	Creatinine; blood	1.9
86833	Antibody to human leukocyte antigens (HLA), solid phase assays (e.g., microspheres or beads, ELISA, Flow cytometry); high-definition qualitative panel for identification of antibody specificities (e.g., individual antigen per bead methodology), HLA Class	1.9
77013	Computed tomography guidance for, and monitoring of, parenchymal tissue ablation	2.6
J2704	Injection, propofol, 10 mg	1.8
76776	Ultrasound, transplanted kidney, real time, and duplex Doppler with image documentation	2.7
J3490	Unclassified drugs	2.2
J0360	Injection, hydralazine HCl, up to 20 mg	1.5
88173	Cytopathology, evaluation of fine needle aspirate; interpretation and report	2.2
99219	Initial observation care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and medical decision making of moderate complexity. Counseling and/or coordination.	1.3
862	Anesthesia for extraperitoneal procedures in lower abdomen, including urinary tract; renal procedures, including upper one-third of ureter, or donor nephrectomy	1.6
50593	Ablation, renal tumor(s), unilateral, percutaneous, cryotherapy	2.6
81025	Urine pregnancy test, by visual color comparison methods	1.5
84520	Urea nitrogen; quantitative	1.2
80061	Lipid panel This panel must include the following: Cholesterol, serum, total (82465) Lipoprotein, direct measurement, high density cholesterol (HDL cholesterol) (83718) Triglycerides (84478)	1.1
76775	Ultrasound, retroperitoneal (e.g., renal, aorta, nodes), real time with image documentation; limited	1.5
99214	Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity. Counseling	1.1
83970	Parathormone (parathyroid hormone)	1.1
82947	Glucose; quantitative, blood (except reagent strip)	1.1
88172	Cytopathology, evaluation of fine needle aspirate; immediate cytohistologic study to determine adequacy for diagnosis, first evaluation episode, each site	1.3
99232	Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of	1.3

J1170	Injection, hydromorphone, up to 4 mg	1.0
99220	Initial observation care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive	0.9
	history; A comprehensive examination; and medical decision making of high complexity. Counseling and/or coordination.	
99233	Subsequent hospital care, per day, for the evaluation and management	1.2
	of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision	
	making of high complexity. Counseling and/or	
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	1.0
84703	Gonadotropin, chorionic (hCG); qualitative	1.1
83036	Hemoglobin; glycosylated (A1C)	0.9
J7050	Infusion, normal saline solution, 250 cc	0.9
88312	Special stain including interpretation and report; Group I for microorganisms (e.g., acid fast, methenamine silver)	1.1
Q9967	Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	0.8
J1200	Injection, diphenhydramine HCl, up to 50 mg	0.8
81003	Urinalysis, by dip stick or tablet reagent for bilirubin, glucose,	0.8
	hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity,	
	urobilinogen, any number of these constituents; automated, without microscopy	
87086	Culture, bacterial; quantitative colony count, urine	0.8
87497	Infectious agent detection by nucleic acid (DNA or RNA);	0.8
0/43/	cytomegalovirus, quantification	0.0
99218	Initial observation care, per day, for the evaluation and management of	0.7
	a patient which requires these 3 key components: A detailed or	
	comprehensive history; A detailed or comprehensive examination; and	
	Medical decision making that is straightforward	
J2597	Injection, desmopressin acetate, per 1 mcg	0.7
J0690	Injection, cefazolin sodium, 500 mg	0.7
G9637	At least two orders for the same high-risk medication	0.7
J7120	Ringers lactate infusion, up to 1000 cc	0.7
85576	Platelet, aggregation (in vitro), each agent	0.8
88307	Level V - Surgical pathology, gross and microscopic examination	0.9
	Adrenal, resection Bone - biopsy/curettings Bone fragment(s),	
	pathologic fracture Brain, biopsy Brain/meninges, tumor resection	
	Breast, excision of lesion, requiring microscopic evaluation.	
99215	Office or other outpatient visit for the evaluation and management of	0.6
	an established patient, which requires at least 2 of these 3 key	
	components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity. Counseling.	
93010	Electrocardiogram, routine ECG with at least 12 leads; interpretation	0.7
22010	and report only	0.7
J1100	Injection, dexamethasone sodium phosphate, 1 mg	0.6

J2270	Injection, morphine sulfate, up to 10 mg	0.6
50592	Ablation, 1 or more renal tumor(s), percutaneous, unilateral, radiofrequency	1.3
80051	Electrolyte panel This panel must include the following: Carbon dioxide (bicarbonate) (82374) Chloride (82435) Potassium (84132) Sodium (84295)	0.6
76770	Ultrasound, retroperitoneal (e.g., renal, aorta, nodes), real time with image documentation; complete	0.9
88314	Special stain including interpretation and report; histochemical stain on frozen tissue block (List separately in addition to code for primary procedure)	0.6
96374	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug	0.7
C2618	Probe/needle, cryoablation	0.5
80180	Mycophenolate (mycophenolic acid)	0.5
99213	Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: An expanded problem focused history; An expanded problem focused examination; Medical decision-making.	0.5
84550	Uric acid; blood	0.5
88334	Pathology consultation during surgery; cytologic examination (eg, touch prep, squash prep), each additional site (List separately in addition to code for primary procedure)	0.8
88331	Pathology consultation during surgery; first tissue block, with frozen section(s), single specimen	0.8